GI Cancers | Clinical

FDA Receives New Drug Application for Ivosidenib in IDH1+ Cholangiocarcinoma

March 01, 2021

A New Drug Application was submitted to the FDA for ivosidenib tablets as a potential treatment option for patients with previously treated IDH1-mutated cholangiocarcinoma. The company is requesting Priority Review be granted to the application.

Unique Findings With Binimetinib Plus Imatinib in Advanced GIST

February 19, 2021

Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib plus imatinib as treatment of patients with untreated advanced gastrointestinal stromal tumors.

The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer

February 15, 2021

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

FDA Grants Priority Review to 1L Nivolumab Combination in Gastric/GEJ/Esophageal Cancers

January 20, 2021

The FDA has granted a Priority Review to the combination of nivolumab with fluoropyrimidine- and platinum-containing chemotherapy, which is a potential treatment option for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.